secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2023-07-25T23:59:59+00:00
Accession:  0000875045-23-000027
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q2 revenue $2.46B (-5% YoY); launches LEQEMBI, announces net $700M cost savings by 2025
--------------------------------------------------------------------------------

- Q2 revenue $2,456M; GAAP EPS $4.07, non-GAAP EPS $4.02; EPS down 44% and 23% YoY respectively.
- Launched Alzheimer's drug LEQEMBI in U.S. during Q2.
- Fit for Growth program: ~$1B gross savings, ~$300M reinvested, net ~$700M by 2025; ~1,000 headcount reduction.
- TECFIDERA EU regulatory protection extended to Feb 2, 2025; new SPINRAZA data in SMA post gene therapy.
- Reaffirmed full-year 2023 guidance; R&D pipeline prioritization substantially complete.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504523000027/0000875045-23-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504523000027/biib-20230725.htm
  HTML page:      https://secwatch.observer/filing/0000875045-23-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer